Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design-Reference-Cited by-同舟云学术

Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design

Published:2013-07-10 Issue:14 Volume:56 Page:5757-5772
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Richters André¹,Ketzer Julia²,Getlik Matthäus¹,Grütter Christian¹,Schneider Ralf³,Heuckmann Johannes M.⁴,Heynck Stefanie⁴,Sos Martin L.⁴,Gupta Anu⁵,Unger Anke⁶,Schultz-Fademrecht Carsten⁶,Thomas Roman K.⁴⁷,Bauer Sebastian²,Rauh Daniel¹³

Affiliation:

1. Department of Chemistry and Chemical Biology, Technical University of Dortmund, Otto-Hahn-Strasse 6, D-44227 Dortmund, Germany

2. Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Duisburg-Essen Medical School, Hufelandstrasse 55, D-45122 Essen, Germany

3. Chemical Genomics Centre of the Max-Planck-Society, Otto-Hahn-Strasse 15, D-44227 Dortmund, Germany

4. Department of Translational Genomics, University of Cologne, Weyertal 115b, D-50931 Cologne, Germany

5. Department of Molecular Genetics, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States

6. Lead Discovery Center GmbH, Otto-Hahn-Strasse 15, D-44227 Dortmund, Germany

7. Department of Pathology, University of Cologne, Joseph-Stelzmann Strasse 9, D-50931 Cologne, Germany

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm4004076

Reference55 articles.

1. Proteus in the World of Proteins: Conformational Changes in Protein Kinases

2. The discovery of receptor tyrosine kinases: targets for cancer therapy

3. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

4. Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy

5. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Electronic and Structural Insights of BCR-ABL Inhibitors Under LMC Treatment Perspective;Research Topics in Bioactivity, Environment and Energy;2022

2. The Oncogenic Protein, Breakpoint Cluster (BCR)-Abelson Kinase (ABL) and Chronic Myelocytic Leukemia (CML): Insight Into the Drug Resistance Mechanisms and Approaches for Targeting BCR-ABL in CML;Reference Module in Biomedical Sciences;2021

3. Recent advances in Bcr‐Abl tyrosine kinase inhibitors for overriding T315I mutation;Chemical Biology & Drug Design;2020-10-29

4. Androgen receptor plasticity and its implications for prostate cancer therapy;Cancer Treatment Reviews;2019-12

5. Research Progress of Diphenyl Urea Derivatives as Anticancer Agents and Synthetic Methodologies;Mini-Reviews in Organic Chemistry;2019-10-08